glp 1 with kidney disease SGLT2 vs GLP-1 for CKD: Which Is Better? The expanding benefits of GLP-1

Yet people looking to take a GLP-1 RA (or glucagon-like peptide 1 receptor agonist) dont have to see a specialist or even their primary care physician to get their hands on these drugs

The current medications vary in mechanism and magnitude: Semaglutide (Ozempic) targets GLP-1 receptors - around 15% average weight loss Tirzepatide (Mounjaro) targets GLP-1 + GIP - around 20% weight loss, often better GI tolerance Retatrutide (Phase 3 Trials) targets three receptors around 24% weight loss in trials, with broader metabolic effects The real risk is muscle mass loss

For weight management, NHS use follows specific NICE technology appraisals (such as TA875 for semaglutide and TA664 for liraglutide) and typically requires specialist service involvement

These are usually temporary and manageable

please reach out today